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http://dx.doi.org/10.1016/j.jacl.2016.06BACKGROUND: TA-8995 is a potent inhibitor of cholesteryl ester transfer protein (CETP) with
beneficial effects on lipids and lipoproteins. The effect of TA-8995 on cholesterol efflux capacity
(CEC), a measure of high-density lipoprotein (HDL) function, and HDL subparticle distribution is
largely unknown.
OBJECTIVE: To assess the effect of the CETP inhibitor TA-8995 on ABCA1- and non–ABCA1-
driven CEC and on HDL particle distribution.
METHODS: Total, non–ABCA1-, and ABCA1-specific CEC from J774 cells and HDL subclass dis-
tribution assessed by two-dimensional gel electrophoresis were measured at baseline and after 12-week
treatment in 187 mild-dyslipidemic patients randomized to placebo, 1 mg, 5 mg, 10 mg TA-8995, or
10 mg TA-8995 combined with 10 mg rosuvastatin (NCT01970215).
RESULTS: Compared with placebo, total, non–ABCA1-, and ABCA1-specific CEC were increased
dose dependently by up to 38%, 72%, and 28%, respectively, in patients randomized to 10 mg of
TA-8995. PreBeta-1 HDL, the primary acceptor for ABCA1-driven cholesterol efflux, was increased
by 36%. This increase in preBeta-1 HDL correlated significantly with the total and the ABCA1-
driven CEC increase, whereas the high-density lipoprotein cholesterol (HDL-C) increase did not.
CONCLUSION: TA-8995 dose dependently increased not only total and non–ABCA1-specific CEC
but also ABCA1-specific CEC and preBeta-1 HDL particle levels. These findings suggest that TA-8995of Vascular Medicine, Academic
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1138 Journal of Clinical Lipidology, Vol 10, No 5, October 2016not only increases HDL-C levels but also promotes functional properties of HDL particles. This CETP
inhibitor–driven preBeta-1 HDL increase is an important predictor of both ABCA1 and total CEC in-
crease, independent of HDL-C increase. Whether these changes in HDL particle composition and func-
tionality have a beneficial effect on cardiovascular outcome requires formal testing in a cardiovascular
outcome trial.
 2016 National Lipid Association. All rights reserved.Introduction
Large prospective studies have shown that plasma levels
of high-density lipoprotein cholesterol (HDL-C) levels are
inversely related with cardiovascular disease (CVD).1
Findings derived from recent Mendelian randomization
studies, however, showed that genetic variants with an ef-
fect on HDL-C levels carry no predictive value for CVD
outcomes.2 In addition, therapeutic interventions that
were designed to increase HDL-C failed to show an effect
on CVD events, and these data have casted doubt on the
causal relation between HDL-C and CVD outcomes.3–5
HDL has been shown to encompass several properties
that protect against atherosclerosis, but the major anti-
atherogenic effect is believed to be its ability to remove
excess cholesterol from macrophages in the arterial wall.6
Indeed, the capacity of plasma to mediate cholesterol efflux
from macrophages is strongly predictive of future cardio-
vascular events, even after adjustment for plasma HDL-
C.7–9 This apparent discrepancy might be explained by
nonfunctional HDL through oxidative modifications sec-
ondary to inflammation.10 Alternatively, the distribution
of HDL particles may be skewed away from subfractions
with a specific efflux receptor affinity. For example, ATP-
binding cassette transporter A1 (ABCA1) transfers cellular
free cholesterol to small nascent preBeta-1 HDL particles,
whereas ABCG1 promotes the efflux of free cholesterol
to larger, more mature alpha HDL particles.11,12
Cholesteryl ester transfer protein (CETP) transfers cho-
lesteryl esters from HDL to apoB-containing lipoproteins,
and CETP inhibitors were initially developed as HDL-C
raising agents, in the assumption that raising HDL-C levels
would result in CVD risk reduction. Indeed, CETP inhibitors
were shown to increase HDL-C and apoA-1 levels, but the
effect size of the different CETP inhibitors on these
parameters varies greatly.3,4,13,14 To date, however, CVD
outcome studies investigating the effect of HDL-C raising
modalities on CVD events have failed to show a beneficial
effect.3,4 These results have spurred a debate on the function-
ality of the HDL that is generated by CETP inhibitors, and it
has been speculated that CETP inhibitors may promote large
nonfunctional HDL particles.15 Against this background, it
has become opportune to study the effects of CETP inhibi-
tion on the distribution of HDL subfractions and to measure
the cholesterol efflux capacity (CEC) of plasma from pa-
tients treated with CETP inhibitors.In a previous study, we found that total CEC was
increased by TA-8995.16 In the present study, we explored
the effects of TA-8995 treatment on non-ABCA1- and
ABCA1-specific CEC, and we assessed CETP inhibitor
driven changes on HDL subparticle distribution and their
correlation with different cholesterol efflux capacities as
well as with lipids and lipoproteins.Material and methods
Study design and participants
The TULIP trial was a multicenter randomized, double-
bind, placebo-controlled, parallel-group, phase 2 trial in
364 patients, distributed over 9 treatment arms.16 The study
was conducted between August 2013 and July 2014 and
was in compliance with the ethical principles in the Decla-
ration of Helsinki, the International Conference on Harmo-
nization/Good Clinical Practice and appropriate regulatory
requirements. The protocol was reviewed and approved by
the institutional review board of each participating center,
and each patient provided written informed consent.
Details on study design have been reported.16 In short,
patients aged 18 to 75 years with mild dyslipidemia were
recruited, defined as low-density lipoprotein cholesterol
(LDL-C) levels between 2.5 and 4.5 mmol/L, HDL-C levels
between 0.8 and 1.8 mmol/L and triglycerides below
4.5 mmol/L. Major exclusion criteria were clinically man-
ifest CVD, type 1 diabetes, poorly controlled type 2 dia-
betes (HBA1C over 8%), or uncontrolled hypertension.Study procedures
Plasma samples used for the analysis were obtained at
baseline and week 12, in a fasted state. CEC was measured by
Vascular Strategies (Horsham, PA) according to methods
previously described7 in subjects randomized to placebo
(n 5 37), 1 mg of TA-8995 (n 5 37), 5 mg of TA-8995
(n 5 39), 10 mg of TA-8995 (n 5 35) as monotherapy,
and 10 mg of TA-8995 combined with 10 mg rosuvastatin
(n 5 39). In short, J774 cells were radiolabeled with 2uCi
of 3H-cholesterol per milliliter. ABCA1 was upregulated by
6-hour incubation with 0.3 mM of 8-(4-chlorophenylthio)
-cyclic-AMP. Medium, containing 2.8% apolipoprotein
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stimulated and unstimulated cells. Liquid scintillation count-
ing was used to quantify the effluxed 3H-cholesterol to the
medium. Total CEC is defined as the efflux measured from
cAMP-stimulated J774 cells. Non–ABCA1-specific CEC
was measured from unstimulated J774 cells. ABCA1-
specific CEC was calculated as the difference between
cAMP-stimulated (total) and unstimulated (non-ABCA1)
cells. In the initial report, we presented the data for total
CEC.16 After analysis of the preBeta-1 HDL two-
dimensional (2D)-gelelectrophoresis data (see in the following
section), we additionally measured ABCA1- and non–
ABCA1-specific CEC (cAMP stimulated and unstimulated)
in plasma samples that were frozen and stored at 280C.
HDL subparticle distribution (preBeta-1, preBeta-2, and
alpha 1-4) was measured in the placebo, 5 mg of TA-8995,
10 mg of TA-8995, and 10 mg of TA-8995 combined with
10 mg of rosuvastatin treatment arms using 2D gel
electrophoresis in plasma from placebo, 5 mg of TA-
8995, 10 mg of TA-8995, and 10 mg of TA-8995 plus
10-mg rosuvastatin–treated subjects according to methods
previously published.17
Statistical analysis
Differences in CEC (total, non–ABCA1-, and ABCA1-
specific) and HDL subparticle distribution were analyzed as
percent change from baseline using analysis of covariance
with baseline values for the respective parameters as a
covariate. HDL subparticle distribution by 2D gel electro-
phoresis is reported for the combined 5-mg TA-8995 and
10-mg TA-8995 monotherapy treatment arms. To address
the contribution of preBeta-1 HDL to cholesterol efflux,
multiple linear regression analysis was used to report the
proportion of variance explained for specific models.
Models with and without percent change from baseline
for HDL-C and preBeta-1 HDL were compared in terms of
R2 change. Regression analysis was performed for base co-
variates (model 1) and either addition of percent change in
HDL-C from baseline (model 2) or addition of percent
change in preBeta-1 HDL from baseline (model 3). Finally,
percent change in preBeta-1 HDL was added to model 2,
resulting in model 4. This model represents the proportion
of variance in CEC additionally explained by preBeta-1
HDL independent of HDL-C increase.Results
Baseline characteristics
The overall baseline characteristics and predefined end
points of the phase 2 study were previously reported.16 We
measured CEC and HDL particle subclasses in a total of
187 participants randomized to receive treatment with
placebo (n 5 37), 1 mg of TA-8995 (n 5 37), 5 mg ofTA-8995 (n 5 39), 10 mg of TA-8995 (n 5 35), or
10 mg of TA-8995 combined with 10 mg of rosuvastatin
(n 5 39). Baseline characteristics were similar between
treatment groups (Supplemental Table S1).
Cholesterol efflux capacity
Total CEC increased in patients randomized to TA-8995,
and this effect was found to be dose dependent by 17%,
33%, and 38% in the patients receiving 1 mg, 5 mg and
10 mg TA-8995, respectively, while CEC increased 31% in
patients on 10-mg TA-8995 plus 10-mg rosuvastatin com-
bination therapy (all P , .001 compared with placebo,
Fig. 1A), as was recently reported.16 Non–ABCA1-
specific CEC increased by 38%, 62%, and 72% in the
groups receiving 1 mg, 5 mg, and 10 mg of TA-8995,
respectively, whereas a 67% increase was observed in pa-
tients randomized to 10 mg of TA-8995 in combination
with 10 mg of rosuvastatin (all P , .001 compared with
placebo, Fig. 1B). ABCA1-specific CEC was increased
by 14%, 25%, and 28% for 1, 5, and 10 mg TA-8995 mono-
therapy (P , .05 for 5 mg and P , .01 for 10 mg TA-8995
compared with placebo). Combination therapy of 10-mg
TA-8995 plus 10-mg rosuvastatin resulted in a nonsignifi-
cant 16% increase in ABCA1-specific CEC, when
compared with placebo. The difference between 10-mg
TA-8995 monotherapy and 10-mg TA-8995 in combination
with 10-mg rosuvastatin was nonsignificant for all analyses.
HDL subparticle distribution
The effect of TA-8995 treatment on HDL subparticle
distribution was measured by 2D-gel-electrophoresis in
subjects receiving placebo, 5 mg of TA-8995, 10 mg of TA-
8995, and 10 mg of TA-8995 combined with 10 mg of
rosuvastatin therapy, Figure 2. The change from baseline
was similar for 5-mg and 10-mg TA-8995 monotherapy;
therefore, we report the combined results for these groups
(results for separate groups; Supplemental Tables S2
and S3).
As expected, large alpha-1 HDL particle levels increased
by 350% and 352% (P , .001) in patients receiving mono-
therapy and combination therapy, respectively. Alpha-2 and
alpha-4 particles were not significantly changed in any
treatment group, whereas alpha-3 HDL was significantly
decreased by 17% from baseline in both monotherapy
and combination therapy (P , .001).
Finally, preBeta-1 HDL, a small discoidal lipid-poor
particle that is the primary acceptor for ABCA1-driven
cholesterol efflux, was significantly increased by 36% for
TA-8995 monotherapy (P , .001); on 10-mg TA-8995
combined with 10-mg rosuvastatin, there was a trend to-
ward an increase (22%), but this was not statistically signif-
icant. The larger preBeta-2 HDL increased by 66% in
patients on monotherapy and by 64% in patients receiving
combination therapy with 10-mg rosuvastatin (P , .001).
A B
C
Figure 1 (A–C) Total (A), non-ABCA1 (B), and ABCA1-specific (C) cholesterol efflux capacity as percent change from baseline. Data
are presented as least squares means 6 standard error of the mean. *P , .05, **P , .01, ***P , .001 compared with placebo. Placebo
(n 5 37), ‘‘1 mg’’ is treatment with 1 mg of TA-8995 monotherapy (n 5 37), ‘‘5 mg’’ is treatment with 5 mg of TA-8995 monotherapy
(n 5 39), ‘‘10 mg’’ is treatment with 10 mg of TA-8995 monotherapy (n 5 35), ‘‘10 mg 1 10 mg’’ is combination therapy of 10 mg of
TA-8995 plus 10 mg rosuvastatin (n 5 39).
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The correlation of HDL-C and preBeta-1 HDL increases
to CEC increases as coefficient of determination (R2) was
assessed using multiple linear regression analysis. The re-
sults of these analyses are summarized in Table 1.
HDL-C increase at week 12 was not significantly
correlated with total and ABCA1-specific CEC increase,
whereas it was significantly correlated with non–ABCA1-
specific CEC increase (R2 change 0.08, P , .001). In
contrast, preBeta-1 HDL increase was significantly corre-
lated with total and ABCA1-specific CEC increase (R2
change 0.16 and 0.15, respectively, P , .001). The correla-
tion with non–ABCA1-specific CEC was smaller (R2
change 0.04, P , .05). Correction for HDL-C increase
did not significantly change the correlation of preBeta-1
HDL with CEC (model 4).
Baseline total CEC was explained for a substantial
proportion by HDL-C and preBeta-1 HDL levels. The
contribution of preBeta-1 HDL to ABCA1-specific CEC at
baseline was larger compared with HDL-C, and contribu-
tion of preBeta-1 to non–ABCA1-specific cholesterol efflux
was small. Altogether, these findings indicate that the
increase in preBeta-1 HDL explains not only a largeproportion of variance in ABCA1-specific CEC but also
that of total CEC, independent of HDL-C increase, further
underlining the importance of preBeta-1 HDL increase in
relation to the observed increase of CEC.
Discussion
Treatment with the CETP inhibitor TA-8995 led to a
significant increase of total, non-ABCA1-, and ABCA1-
specific CEC as well as a significant increase in preBeta-1
HDL levels. The increase in HDL-C did not correlate with
total or ABCA1-specific CEC increase, whereas the
increase in preBeta-1 HDL had a significant correlation
with total and ABCA1-specific CEC. These findings not
only underline the importance of the preBeta-1 HDL
increase in relation to total CEC, a predictor of incident
CVD events, but also confirm the earlier notion that HDL-C
levels and HDL functionality as assessed by CEC are not
necessarily interchangeable. Our data indicate that CETP
inhibition by means of TA-8995 increases preBeta-1 HDL
levels and HDL particle functionality beyond a mere
increase in HDL-C levels.
Although low HDL-C levels are among the strongest
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Figure 2 High-density lipoprotein (HDL) subparticle distribution as percent change from baseline as measured by 2D gel electrophoresis.
Data are presented as least squares means 6 standard error of the mean. (A) shows preBeta-1, preBeta-2, alpha-4, alpha-3, alpha-2, and
alpha-1 results for placebo (n 5 36), monotherapy (5 mg 1 10 mg TA-8995, n 5 72) and combination therapy: 10 mg of TA-8995 plus
10 mg rosuvastatin (n 5 39). (B) shows the specific preBeta-1 data for placebo (n 5 36), ‘‘5 mg’’ is treatment with 5 mg of TA-8995
(n 5 36), ‘‘10 mg’’ is treatment with 10 mg of TA-8995 (n 5 34) and ‘‘10 mg 1 10 mg’’ is combination therapy 10 mg TA-8995 plus
10 mg rosuvastatin (n 5 39). *P , .05, **P , .01, ***P , .001 compared with placebo.
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levels have casted doubt on the clinical utility of increasing
total HDL-C levels. These findings have shifted the HDL-C
hypothesis toward HDL functionality as a mediator of HDL-
related atheroprotection.2 One of the key antiatherogenic
properties of the HDL particle is its role in the process of
efflux of cholesterol from peripheral tissues to the circula-
tion, where the HDL particle is the main acceptor. In recent
years, in vitro models have been developed to reliably and
reproducibly measure this capacity.7 CEC, measured by the
same methodology as in our study, was previously shown
to be strongly and inversely related to coronary heart disease
in a cross-sectional approach and in large prospective co-
horts.7–9 It is of note that HDL-C levelswere only aweak pre-
dictor for cholesterol efflux in those studies.
Although all CETP inhibitors have been shown to
induce an increase in HDL-C levels, the effects of
dalcetrapib vary to a great extent from those observed forthe potent CETP inhibitors anacetrapib, evacetrapib, and
TA-8995. HDL-C levels were shown to increase by 33% in
patients randomized to a daily dose of 300 mg of
dalcetrapib, whereas anacetrapib, evacetrapib, and TA-
8995 achieved HDL-C increases up to 179%.4,13,14,16 Simi-
larly, the effects of CETP inhibitors on HDL-functionality
and CEC vary greatly. A clinical trial investigating the
CETP inhibitor dalcetrapib in patients with acute coronary
syndrome showed that dalcetrapib increased total CEC by
9.5% with no effect on ABCA1-specific CEC or
preBeta-1 HDL levels.18 In contrast, treatment with the
CETP inhibitors anacetrapib and evacetrapib has been
shown to increase both total CEC and ABCA1-specific
CEC, to about the same extent as TA-8995.19,20 Hence,
the increase of CEC is likely a CETP inhibitor class effect,
with the potent compounds, anacetrapib, evacetrapib, and
TA-8995, having a more pronounced effect on total and
ABCA1-driven components of CEC.
Table 1 Contribution of high-density lipoprotein cholesterol (HDL-C) and PreBeta1 high-density lipoprotein (HDL) to cholesterol
efflux capacity (CEC) levels at baseline and after 12 weeks treatment with TA 5 8995 as regression coefficient of determination
Model
Baseline values Total CEC ABCA1-specific CEC Non–ABCA1-specific CEC
Covariates R2 R2 change P value R2 R2 change P value R2 R2 change P value
Model 1 Age, gender, BMI, smoking status 0.03 — — 0.02 — — 0.09 — —
Model 2 Model 1 1 base HDL-C 0.17 0.14 ,.001 0.04 0.02 ns 0.39 0.31 ,.001
Model 3 Model 1 1 base prebeta1 HDL 0.25 0.22 ,.001 0.12 0.10 ,.001 0.15 0.06 ,.01
Model 4 Model 2 1 base PreBeta1 HDL 0.31 0.14 ,.001 0.12 0.08 ,.001 0.40 0.01 ns
12 wk TA-8995 monotherapy
Model 1 Age, gender, BMI, smoking status,
baseline cholesterol efflux
parameter
0.28 — — 0.54 — — 0.56 — —
Model 2 Model 1 1 %HDL-C increase
from baseline
0.29 0.02 ns 0.56 0.02 ns 0.64 0.08 ,.001
Model 3 Model 1 1 %preBeta1 increase
from baseline
0.43 0.16 ,.001 0.69 0.15 ,.001 0.59 0.04 ,.05
Model 4 Model 2 1 %PreBeta1 increase
from baseline
0.44 0.14 ,.001 0.69 0.14 ,.001 0.66 0.02 ,.05
BMI, body mass index; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; ns, nonsignificant.
Multiple linear regression analysis with total, ABCA1- and non–ABCA1-specific CEC levels at baseline and after 12 weeks of treatment with TA-8995
monotherapy as independent parameters and specified models 1-4 as predictors. Results are presented as R2, R2 change, and corresponding P value for
each specified model.
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larger, more mature HDL particles, which is reflected in the
robust increase in large alpha-1 HDL particles up to 350%
observed in our study. As non–ABCA1-specific efflux is
mainly driven by ABCG1 and SRB1 efflux to large HDL
particles,11,12 this fits with the observed increase in non–
ABCA1-specific CEC up to 72% at the 10 mg dose of TA-
8995. However, the finding that ABCA1-specific CEC and
small lipid-poor preBeta-1 HDL levels, the primary acceptor
for ABCA1-mediated efflux, are increased on CETP inhibi-
tion is counterintuitive and poorly understood. To underline
the importance of preBeta-1 HDL increase in relation to
CEC, we showed that preBeta-1 HDL, independent of
HDL-C increase, is an important predictor not only of
ABCA1-specific but also of total CEC increase. In contrast,
HDL-C increase was not correlated with total CEC increase,
despite the 179% increase in HDL-C from baseline.
Currently, it is largely unknown how preBeta-1 HDL is
synthesized, and the mechanism linking CETP inhibition
with increased preBeta-1 levels remains to be elucidated.
One of the possible explanations is that CETP inhibition
results in increased apoA-1 synthesis from the liver, which
consequently leads to increased plasma preBeta-1 HDL
levels. It has been shown that a significant fraction of apoA-
1 undergoes intracellular lipidation and is released as nascent
HDL from hepatocytes.21 Alternatively, preBeta-1 HDL may
originate from the degradation of very low–density lipopro-
tein and other triglyceride-rich lipoproteins, which are a
potential source of preBeta-1 HDL.22 Indeed, it was recently
shown that CETP inhibition does result in increased clear-
ance and lipolysis of triglyceride-rich lipoproteins.23It is anticipated that patients who would potentially
qualify for CETP inhibition are likely to be cotreated with
statins. Therefore, it is reassuring that total and non–
ABCA1-specific CEC were still significantly increased in
patients randomized to the combination of 10-mg TA-8995
and 10-mg rosuvastatin. However, it was clearly diminished
in patients on dual therapy, compared with patients
receiving TA-8995 alone. In fact, it was recently shown
that statin treatment actually lowers both preBeta-1 levels
and ABCA1-specific and total CEC.20 Hence, the observed
nonsignificant increase in ABCA1-specific CEC in patients
randomized to TA-8995 combined with a statin is likely
caused by the reduction of CEC by statin treatment.
Recently, the ACCELERATE trial, investigating the
effect of evacetrapib in patients with established CVD at
high residual risk, was terminated for futility,24 fueling the
question why the efflux increase has not resulted in clinical
benefit. No formal answer can be provided because study re-
sults and a complete data analysis are still to be awaited.
Nevertheless, baseline characteristics and sample size con-
siderations have been recently reported and provide some
clues for the lack of clinical benefit. First, baseline LDL-C
of 2.10 mmol/L was low and indicative of a well-
controlled population, which was also reflected by 98% of
study population receiving statin therapy.25 Absolute LDL-
C reduction will be small in this population. A second
concern is the diminished efficacy of evacetrapib to reduce
apoB levels (as a substitute for low-density lipoprotein
[LDL] particle numbers) in combination with statins
compared with evacetrapib monotherapy,14 an effect also
observed for TA-8995 in the TULIP trial.16 LDL-C lowering
van Capelleveen et al TA-8995 increases cholesterol efflux capacity 1143by CETP inhibition combined with statins is partly a reflec-
tion of CETP-mediated intravascular remodeling of LDL
particles and only partly the consequence of LDL receptor
mediated clearance of LDL particles. Therefore, the LDL-
C reduction by CETP inhibition in combination with statins
will likely overestimate the potential CVD risk reduction.
Third, ACCELERATE-enrolled high-risk coronary artery
disease patients of which an unexpected large proportion
were diabetic patients (63.7%), and efflux potential never
investigated in either category.20 Fourth, over 30% of
participants in ACCELERATE experienced a recent acute
coronary syndrome, on average 5.5 months before random-
ization. Previous LDL-C intervention studies have taught us
to be cautious in our expectation of clinical benefit from
LDL-C lowering in the first year after acute coronary syn-
drome, as a proportion of subsequent events are considered
nonmodifiable or refractory to lipid-lowering interventions.
In combination with the relatively short follow-up time of
25 months, all these factors combined might have seriously
restricted power, considering the small sample size of 12.000
patients. In contrast to ACCELERATE, the phase III study
REVEAL, investigating the potent CETP inhibitor anacetra-
pib has recently passed futility assessment.26 Where study
power is an issue in ACCELERATE, REVEAL has enrolled
over 30,000 subjects and is therefore assumed to have supe-
rior power over ACCELERATE.
Finally, it should be stressed that ACCELERATE was
never designed or powered to test the clinical utility of
raising CEC, and therefore, this important clinical question
remains to be answered. Post-hoc analyses from ACCEL-
ERATE and REVEAL will have to be awaited.
In conclusion, we report that potent CETP inhibition by
TA-8995 raises not only non–ABCA1-specific CEC but
also ABCA1-specific efflux and small nascent preBeta-1
HDL levels. The preBeta-1 HDL increase is an important
predictor of both ABCA1-and total CEC increase, inde-
pendent of HDL-C increase. The mechanism linking CETP
inhibition and preBeta-1 HDL formation as well as the role
of statin therapy in this process remain to be determined.
CETP inhibition with TA-8995 has now been linked to
large decreases of atherogenic lipoproteins, as well as to an
improvement in the functionality of antiatherogenic lipo-
proteins, a similar profile as shown for evacetrapib and
anacetrapib before. The recent termination for futility of
ACCELERATE might well be due to specific trial-related
issues in combination with untoward consequences of the
combination of statin and CETP inhibitors. We will further
need to wait for the final results of REVEAL, which
recently did pass futility assessment, for a final verdict on
CEC induction by CETP inhibition as a therapeutic target.Acknowledgment
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Table S1 Baseline characteristics per treatment group







10 mg TA-8995 1 10 mg
rosuvastatin (n 5 39)
Age (y) 64.9 6 5.7 66.2 6 6.1 65.2 6 7.7 65.9 6 4.8 63.4 6 6.1
Male (n) 35 (94.6%) 29 (78.4%) 35 (89.7%) 26 (74.3%) 33 (84.6%)
BMI (kg/m2) 26.1 6 1.8 26.5 6 2.8 26.3 6 2.7 25.8 6 2.5 26.3 6 3.5
Total cholesterol, (mmol/L) 5.81 6 0.54 5.60 6 0.73 5.63 6 0.73 5.65 6 0.62 5.60 6 0.70
LDL-C (mmol/L) 3.83 6 0.50 3.61 6 0.61 3.60 6 0.55 3.59 6 0.56 3.62 6 0.56
HDL-C (mmol/L) 1.34 6 0.26 1.34 6 0.24 1.28 6 0.23 1.31 6 0.25 1.34 6 0.31
Triglycerides (mmol/L) 1.37 (1.00–1.66) 1.34 (1.10–1.69) 1.36 (0.97–1.73) 1.53 (1.02–2.14) 1.21 (0.94–1.79)
ApoA-1 (gr/L) 1.44 6 0.18 1.41 6 0.15 1.41 6 0.17 1.41 6 0.17 1.40 6 0.20
ApoB (gr/L) 1.04 6 0.12 0.99 6 0.19 1.01 6 0.16 1.00 6 0.16 1.00 6 0.13
ApoE (gr/L) 0.038 6 0.009 0.039 6 0.010 0.037 6 0.010 0.040 6 0.015 0.037 6 0.009
PreBeta-1 (mg/dL) 13.9 6 3.4 n/a 14.7 6 3.8 13.8 6 4.1 13.3 6 3.4
PreBeta-2 (mg/dL) 4.1 6 1.1 n/a 4.1 6 1.3 4.3 6 1.3 4.1 6 1.2
Alpha-4 (mg/dL) 16.8 6 3.2 n/a 15.6 6 3.5 16.7 6 3.5 16.7 6 3.5
Alpha-3 (mg/dL) 25.4 6 3.8 n/a 24.3 6 4.5 25.2 6 4.1 24.4 6 4.2
Alpha-2 (mg/dL) 55.9 6 10.5 n/a 52.0 6 9.1 55.0 6 9.5 53.6 6 11.0
Alpha-1 (mg/dL) 25.7 6 8.4 n/a 23.6 6 8.3 25.1 6 8.3 26.2 6 9.9
Total CEC 12.7 6 2.3 12.5 6 2.4 10.8 6 1.8 12.5 6 2.6 12.3 6 2.2
ABCA1-specific CEC 6.9 6 1.8 6.6 6 1.9 5.3 6 1.5 6.7 6 1.9 6.5 6 1.8
Non–ABCA1-specific CEC 5.8 6 1.0 5.9 6 0.9 5.5 6 0.7 5.7 6 1.0 5.8 6 0.9
BMI, body mass index; CEC, cholesterol efflux capacity; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; n/a,
not available.
Data are presented as mean 6 standard deviation.
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10 mg TA-8995 1 10 mg
rosuvastatin (n 5 39)
Total cholesterol, (mmol/L) 5.78 6 0.64 5.49 6 0.89 5.74 6 0.80 6.10 6 0.72 5.15 6 0.84
LDL-C (mmol/l) 3.82 6 0.52 2.62 6 0.60 1.86 6 0.45 1.87 6 0.53 1.32 6 0.56
HDL-C (mmol/L) 1.36 6 0.26 2.36 6 0.54 3.29 6 0.53 3.61 6 0.61 3.36 6 0.65
Triglycerides (mmol/L) 1.27 (0.88–1.47) 1.03 (0.89–1.23) 1.14 (0.98–1.49) 1.18 (0.92–1.49) 0.95 (0.81–1.23)
ApoA-1 (gr/L) 1.46 6 0.21 1.86 6 0.29 2.22 6 0.28 2.31 6 0.23 2.16 6 0.26
ApoB (gr/L) 1.02 6 0.14 0.78 6 0.14 0.66 6 0.10 0.65 6 0.12 0.54 6 0.12
ApoE (gr/L] 0.038 6 0.10 0.046 6 0.18 0.049 6 0.016 0.061 6 0.025 0.055 6 0.017
PreBeta-1 (mg/dL) 14.0 6 3.7 n/a 19.0 6 6.1 18.0 6 8.2 16.2 6 5.3
PreBeta-2 (mg/dL) 4.3 6 1.1 n/a 6.3 6 1.9 7.4 6 2.0 6.7 6 2.3
Alpha-4 (mg/dL) 16.4 6 3.2 n/a 16.3 6 3.6 16.5 6 4.8 15.8 6 3.3
Alpha-3 (mg/dL) 27.1 6 5.6 n/a 19.7 6 3.6 20.6 6 4.2 19.7 6 3.2
Alpha-2 (mg/dL) 55.6 6 11.9 n/a 55.4 6 9.4 57.2 6 9.7 53.6 6 8.3
Alpha-1 (mg/dL) 25.5 6 8.6 n/a 97.5 6 20.1 110.9 6 24.5 104.8 6 27.9
Total CEC 13.0 6 2.8 15.2 6 3.2 15.6 6 2.3 18.2 6 4.1 17.0 6 3.4
ABCA1-specific CEC 7.0 6 2.2 7.1 6 2.1 6.6 6 1.7 8.4 6 2.9 7.3 6 2.3
Non–ABCA1-specific CEC 6.0 6 1.0 8.0 6 1.4 9.0 6 1.1 9.8 6 1.7 9.7 6 1.6
CEC, cholesterol efflux capacity; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; n/a, not available.
Data are presented as mean 6 SD.
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10 mg TA-8995 1 10 mg
rosuvastatin (n 5 39)
Total cholesterol (mmol/L) 20.4 6 9.1 21.4 6 13.5 2.3 6 10.9 8.8 6 15.1** 27.8 6 11.0
LDL-C (mmol/L) 0.2 6 11.7 227.0 6 13.1*** 248.7 6 9.1*** 246.4 6 16.8*** 263.7 6 15.7***
HDL-C (mmol/L) 1.8 6 11.0 76 6 26.4*** 160.9 6 42.3*** 180.6 6 42.1*** 156.5 6 52.0***
Triglycerides (mmol/L) 22.6 6 28.9 216.7 6 21 211.4 6 28.5 27.7 6 42.3 217.8 6 28.9
ApoA-1 (gr/L) 1.5 6 10.7 31.9 6 15.8*** 58.3 6 18.2*** 65.1 6 18.6*** 55.8 6 22.4***
ApoB (gr/L) 20.5 6 13.2 219.2 6 14.1*** 233.8 6 11.1*** 233.6 6 15.3*** 245.3 6 12.3***
PreBeta-1 (%) 1.9 6 6.9 n/a 34.6 6 6.7** 36.9 6 7.1** 21.5 6 6.6
PreBeta-2 (%) 7.0 6 5.0 n/a 55.8 6 4.9*** 76.9 1 5.2*** 63.3 6 4.8***
Alpha-1 (%) 7.1 6 17.9 n/a 337.6 6 17.5*** 364.6 6 18.4*** 352.1 6 17.2***
Alpha-2 (%) 2.2 6 3.2 n/a 7.0 6 3.1 5.8 6 3.3 3.8 6 3.1
Alpha-3 (%) 8.4 6 2.9 n/a 218.9 6 2.8*** 216.6 6 3.0*** 217.2 6 2.8***
Alpha-4 (%) 1.3 6 3.7 n/a 4.5 6 3.7 2.7 6 3.8 21.7 6 3.6
Total CEC (%) 26.7 6 2.9 16.8 6 2.9*** 33.2 6 2.8*** 38.3 6 3.0*** 31.1 6 2.8***
ABCA1 CEC (%) 3.9 6 5.0 13.5 6 5.0 24.8 6 5.1* 28.3 6 5.1** 15.6 6 4.8
Non-ABCA1 CEC (%) 4.3 6 3.0 37.8 6 3.0*** 62.4 6 3.0*** 72.2 6 3.1*** 67.4 6 2.9***
CEC, cholesterol efflux capacity; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; n/a, not available.
Data are presented as least-squares means. For 1 mg of TA-8995, no 2D gel electrophoresis data are available. *P , .05; **P , .01; ***P , .001
compared to placebo.
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